Breaking News

DMAC

DiaMedica Therapeutics

07/07/22 Lake Street: DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street

07/07/22 Craig-Hallum: DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum

07/07/22 Oppenheimer: DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer

Clear This Search Refresh Search

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Earnings	DiaMedica Therapeutics reports Q1 EPS (20c), consensus (16c) » 16:30 05/15/23 05/15 16:30 05/15/23 16:30 DMAC DiaMedica Therapeutics $2.00 / +0.37 (+22.70%) DiaMedica plans to file a… DiaMedica plans to file a clinical hold response with the U.S. Food and Drug Administration (FDA) by the end of the week. This request for lifting the clinical hold will include the submission of requested additional supporting data to address prior issues that led to the clinical hold in July 2022. DiaMedica has completed supplemental in-use studies as requested by the FDA. These studies, performed at an independent laboratory, were conducted in two parts. Part 1 simulated actual use of DM199 administration in a hospital setting and Part 2 evaluated worst-case scenarios such as varying storage durations, temperature(s) and light exposure to DM199. DiaMedica believes data from Part 1 confirmed its conclusions from prior testing that the intravenous (IV) dose administered in the ReMEDy2 study was higher than planned due to the change in IV bag materials and was the cause of the hypotension. Accordingly, a dose revision in ReMEDy2 from 1.0 microgram/kg to 0.5 microgram/kg should avoid or minimize the risk of clinically significant hypotension while still reaching what we believe will be a therapeutic blood concentration level. Additionally, results from part 2 of the in-use study were substantially consistent with Part 1 indicating that no special handling instructions should be required. These results are also similar to the Company's IV bag study completed in the fall of 2022. The Company further notes that there are no proposed changes to the ensuing three weeks of subcutaneous dosing under the study protocol. "With the pending submission of our request to lift the clinical hold, we are optimistic that we have fully identified the cause for last year's unexpected hypotensive events and have provided the FDA with adequate data to support our position and allow the FDA to lift the clinical hold," commented Rick Pauls, DiaMedica's Chief Executive Officer. "We look forward to receiving the FDA's response and hope to then be able to resume our work advancing the science of stroke care." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DMAC DiaMedica Therapeutics $2.00 / +0.37 (+22.70%) 04/11/23 DiaMedica Therapeutics appoints David Wambeke CBO 03/10/23 DiaMedica Therapeutics says does not hold deposits at Silicon Valley Bank DMAC DiaMedica Therapeutics $2.00 / +0.37 (+22.70%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $2.00 / +0.37 (+22.70%) 03/28/23 DiaMedica Therapeutics reports FY22 EPS (52c), consensus (52c) DMAC DiaMedica Therapeutics $2.00 / +0.37 (+22.70%) 04/17/23 Fly Insider: Better Therapeutics, AMD among week's notable insider transactions 05/16/23 DiaMedica Therapeutics - DMAC 05/17/23 DiaMedica Therapeutics Inc.

Over a month ago
On The Fly	Fly Insider: Better Therapeutics, AMD among week's notable insider transactions » 14:55 04/17/23 04/17 14:55 04/17/23 14:55 BTTX Better Therapeutics $1.41 / +0.075 (+5.62%) , ALOT AstroNova $14.60 / -0.12 (-0.82%) , DMAC DiaMedica Therapeutics $1.61 / +0.025 (+1.58%) , SMPL Simply Good Foods $35.86 / +0.16 (+0.45%) , AMD AMD $89.07 / -2.65 (-2.89%) , AAPL Apple $164.39 / -0.83 (-0.50%) , FDX FedEx $229.59 / -0.985 (-0.43%) , COIN Coinbase $67.25 / -2.63 (-3.76%) Welcome to "Fly Insider,"… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SMPL FDX DMAC COIN BTTX AMD ALOT AAPL SMPL Simply Good Foods $35.86 / +0.16 (+0.45%) 04/10/23 Simply Good Foods COO buys $250K in common stock 01/30/23 Simply Good Foods says Geoff Tanner, named COO, CEO-elect of company 11/01/22 Freshpet names Todd Cunfer as new CFO 10/27/22 Simply Good Foods announces Shaun Mara as CFO FDX FedEx $229.59 / -0.985 (-0.43%) 04/13/23 FedEx director buys $249K in common stock 04/05/23 FedEx CEO: We are going to get significantly more efficient 04/05/23 FedEx jumps 3% after announcing dividend hike and cost reduction actions 04/05/23 FedEx increases 2024 dividend 10% to $5.04 per share DMAC DiaMedica Therapeutics $1.61 / +0.025 (+1.58%) 04/11/23 DiaMedica Therapeutics appoints David Wambeke CBO 03/10/23 DiaMedica Therapeutics says does not hold deposits at Silicon Valley Bank 10/26/22 DiaMedica Therapeutics provides update on ReMEDy2 trial COIN Coinbase $67.25 / -2.63 (-3.76%) 04/17/23 Crypto names slide as bitcoin retreats below $29,500 04/05/23 Cathie Wood's ARK Investment bought 147K shares of Coinbase today 04/03/23 Coinbase lists Signature Bank as option for customer funds 03/24/23 Cathie Wood's ARK Investment bought 185.2K shares of Coinbase today BTTX Better Therapeutics $1.41 / +0.075 (+5.62%) 04/12/23 Better Therapeutics directors buy $500K, CEO buys $200K in common stock 12/08/22 Better Therapeutics announces LivVita study met its primary endpoint 10/27/22 Better Therapeutics says Diane Gomez-Thinnes joins company as CCO AMD AMD $89.07 / -2.65 (-2.89%) 04/13/23 AMD announces AMD Radeon PRO W7000 Series graphics 04/10/23 Global PC shipments fell 29% in first quarter of 2023, IDC reports 04/06/23 AMD launches AMD Alveo MA35D media accelerator 04/05/23 Samsung Electronics, AMD extend strategic IP licensing agreement ALOT AstroNova $14.60 / -0.12 (-0.82%) 04/12/23 AstroNova director Michas acquires 66,952 common shares AAPL Apple $164.39 / -0.83 (-0.50%) 04/17/23 Apple launches high-yield Savings account for Apple Card users 04/17/23 Apple opens first Apple Store in India 04/13/23 Apple intends to use 100% recycled cobalt in batteries by 2025 04/10/23 Domino's to let users order food via Apple CarPlay BTTX ALOT DMAC SMPL AMD AAPL FDX COIN BTTX Better Therapeutics $1.41 / +0.075 (+5.62%) 04/14/23 Lake Street Better Therapeutics price target lowered to $5 from $6 at Lake Street 03/31/23 Chardan Better Therapeutics price target lowered to $9 from $14 at Chardan 11/15/22 Chardan Better Therapeutics price target lowered to $14 from $17 at Chardan 07/29/22 Chardan Better Therapeutics price target raised to $17 from $15 at Chardan ALOT AstroNova $14.60 / -0.12 (-0.82%) DMAC DiaMedica Therapeutics $1.61 / +0.025 (+1.58%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer SMPL Simply Good Foods $35.86 / +0.16 (+0.45%) 04/13/23 Stifel Simply Good Foods resumed with a Buy at Stifel 04/06/23 Deutsche Bank Simply Good Foods price target lowered to $42 from $43 at Deutsche Bank 04/05/23 Goldman Sachs Simply Good Foods' slowdown due to softer demand for Atkins, Goldman Sachs says 03/31/23 UBS Simply Good Foods price target raised to $45 from $42 at UBS AMD AMD $89.07 / -2.65 (-2.89%) 04/12/23 Cleveland Research AMD estimates lowered below consensus at Cleveland Research 04/11/23 Citi March notebook shipments above expectations, says Citi 04/11/23 KeyBanc AMD price target raised to $110 from $95 at KeyBanc 04/10/23 Piper Sandler AMD price target raised to $110 from $90 at Piper Sandler AAPL Apple $164.39 / -0.83 (-0.50%) 04/17/23 Wedbush Apple doubling down on India market, says Wedbush 04/13/23 Benchmark Benchmark says Cirrus Logic investors should 'opportunistically add' on pullback 04/13/23 Canaccord Apple price target raised to $180 from $170 at Canaccord 04/13/23 Credit Suisse Apple price target raised to $188 from $184 at Credit Suisse FDX FedEx $229.59 / -0.985 (-0.43%) 04/06/23 Loop Capital FedEx price target raised to $263 from $241 at Loop Capital 04/06/23 BMO Capital FedEx price target raised to $260 from $235 at BMO Capital 04/06/23 TD Cowen FedEx price target raised to $280 from $235 at TD Cowen 04/06/23 Morgan Stanley FedEx price target raised to $180 from $145 at Morgan Stanley COIN Coinbase $67.25 / -2.63 (-3.76%) 04/14/23 Barclays Coinbase price target raised to $74 from $70 at Barclays 04/13/23 Raymond James Higher crypto prices not driving volumes for Coinbase, says Raymond James 04/13/23 Mizuho Coinbase volumes not boosted by bitcoin rally, says Mizuho 04/06/23 BofA Coinbase price target raised to $45 from $38 at BofA SMPL FDX DMAC COIN BTTX AMD AAPL SMPL Simply Good Foods $35.86 / +0.16 (+0.45%) 04/05/23 Simply Good Foods sees 2023 net sales up slightly greater than 4%-6% 04/05/23 Simply Good Foods reports Q2 adjusted EPS 32c, consensus 29c 01/05/23 Simply Good reaffirms FY23 net sales view of up slightly greater than 4%-6% 01/05/23 Simply Good Foods reports Q1 adjusted EPS 42c, consensus 40c FDX FedEx $229.59 / -0.985 (-0.43%) 03/16/23 FedEx raises FY23 EPS view before-MTM ex-costs $14.60-$15.20, consensus $13.56 03/16/23 FedEx reports Q3 EPS $3.41, consensus $2.73 03/16/23 Notable companies reporting after market close 12/20/22 FedEx sees FY23 EPS before-MTM ex-costs $13-$14, consensus $14.08 DMAC DiaMedica Therapeutics $1.61 / +0.025 (+1.58%) 03/28/23 DiaMedica Therapeutics reports FY22 EPS (52c), consensus (52c) 11/09/22 DiaMedica Therapeutics reports Q3 EPS (12c), consensus (15c) COIN Coinbase $67.25 / -2.63 (-3.76%) 02/21/23 Coinbase reports Q4 EPS ($2.46) vs. $3.32 y/y 02/21/23 Notable companies reporting after market close 01/10/23 Coinbase sees FY22 adjusted EBITDA within negative $500M loss 'guardrail' 12/07/22 Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more BTTX Better Therapeutics $1.41 / +0.075 (+5.62%) 03/30/23 Better Therapeutics reports Q4 EPS (37c), consensus (51c) 11/14/22 Better Therapeutics reports Q3 EPS (48c), consensus (48c) AMD AMD $89.07 / -2.65 (-2.89%) 01/31/23 AMD sees Q1 revenue $5.3B +/- $300M, consensus $5.48B 01/31/23 AMD reports Q4 EPS 69c, consensus 67c 01/31/23 Notable companies reporting after market close 11/01/22 AMD cuts FY22 revenue view to $23.5B +/- $300M from $26.3B +/- $300M AAPL Apple $164.39 / -0.83 (-0.50%) 02/02/23 Apple reports Q1 EPS $1.88, consensus $1.94 02/02/23 Notable companies reporting after market close 10/27/22 Apple reports Q4 EPS $1.29, consensus $1.17 10/27/22 Notable companies reporting after market close FDX COIN AMD AAPL FDX FedEx $229.59 / -0.985 (-0.43%) 02/07/23 Southwest, FedEx planes may have come within 100 feet of each other, WSJ reports 02/01/23 FedEx cutting management positions by over 10%, Bloomberg reports 02/01/23 FedEx cutting management positions by over 10%, Bloomberg reports 01/10/23 FedEx reduces Sunday deliveries 'again' amid e-commerce decline, Bloomberg says COIN Coinbase $67.25 / -2.63 (-3.76%) 03/17/23 Coinbase plans to potentially set up overseas crypto platform, Bloomberg reports 03/13/23 Bear Cave blog sees 'more problems' at Coinbase 03/08/23 JPMorgan ends banking relationship with Gemini, CoinDesk reports 03/07/23 Judge says Binance.US can proceed to buy Voyager Digital's assets, CoinDesk says AMD AMD $89.07 / -2.65 (-2.89%) 04/05/23 EU to likely strike agreement on Chips Act on April 18, Reuters reports 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says 03/10/23 U.S. to further tighten chip gear export to China restrictions, Bloomberg says 03/02/23 Third Point's Loeb took passive AMD stake amid selloff, CNBC reports AAPL Apple $164.39 / -0.83 (-0.50%) 04/17/23 Leaks show iPhone 15 may contain capacitive buttons, BGR reports 04/14/23 Apple testing Mac laptop with larger display, better processors, Bloomberg says 04/14/23 Apple testing Mac laptop with larger display, better processors, Bloomberg says 04/13/23 Apple now makes about 7% of iPhones in India, Bloomberg reports SMPL FDX COIN BTTX AMD AAPL SMPL Simply Good Foods $35.86 / +0.16 (+0.45%) 04/05/23 Fly Intel: Pre-market Movers 01/05/23 What You Missed On Wall Street On Thursday 01/05/23 What You Missed On Wall Street This Morning FDX FedEx $229.59 / -0.985 (-0.43%) 04/06/23 What You Missed On Wall Street On Thursday 04/06/23 Buy/Sell: Wall Street's top 10 stock calls this week 04/06/23 What You Missed On Wall Street This Morning 04/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations COIN Coinbase $67.25 / -2.63 (-3.76%) 03/27/23 What You Missed On Wall Street On Monday 03/27/23 What You Missed On Wall Street This Morning 03/25/23 Short Report: Surprise GameStop profit spooks bears 03/24/23 What You Missed On Wall Street On Friday BTTX Better Therapeutics $1.41 / +0.075 (+5.62%) 03/30/23 Fly Intel: Pre-market Movers AMD AMD $89.07 / -2.65 (-2.89%) 03/31/23 Here's What You Missed in Crypto This Week 03/24/23 Here's What You Missed in Crypto This Week 03/17/23 Here's What You Missed in Crypto This Week 03/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations AAPL Apple $164.39 / -0.83 (-0.50%) 04/14/23 What You Missed On Wall Street On Friday 04/13/23 What You Missed On Wall Street On Thursday 04/13/23 What You Missed On Wall Street This Morning 04/12/23 What You Missed On Wall Street This Morning 04/28/23 Healthcare 05/04/23 Apple - AAPL 06/20/23 FedEx - FDX 05/17/23 DiaMedica Therapeutics Inc. 05/18/23 Advanced Micro Devices FDX COIN AMD AAPL FDX FedEx $229.59 / -0.985 (-0.43%) 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th 03/17/23 Early notable gainers among liquid option names on March 17th 03/16/23 Fedex options imply 5.1% move in share price post-earnings COIN Coinbase $67.25 / -2.63 (-3.76%) 03/16/23 Largest borrow rate increases among liquid names 02/21/23 Coinbase options imply 14.4% move in share price post-earnings 02/03/23 Coinbase call buyer realizes 37% same-day gains 01/11/23 Unusually active option classes on open January 11th AMD AMD $89.07 / -2.65 (-2.89%) 03/22/23 Early notable gainers among liquid option names on March 22nd 03/17/23 Unusually active option classes on open March 17th 03/16/23 Early notable gainers among liquid option names on March 16th 02/23/23 Unusually active option classes on open February 23rd AAPL Apple $164.39 / -0.83 (-0.50%) 04/14/23 Notable open interest changes for April 14th 04/10/23 Notable open interest changes for April 10th 04/06/23 Apple call buyer realizes 2% same-day gains 04/04/23 Notable open interest changes for April 4th
Hot Stocks	DiaMedica Therapeutics appoints David Wambeke CBO » 08:43 04/11/23 04/11 08:43 04/11/23 08:43 DMAC DiaMedica Therapeutics $1.55 / -0.1 (-6.06%) DiaMedica Therapeutics … DiaMedica Therapeutics announced the appointment of David Wambeke, as Chief Business Officer CBO . In this position, he will lead business development, including financing and partnering strategies, and acceleration of prioritized development programs, as well as other business operations. ShowHide Related Items >><< Company News Street Research Earnings Events DMAC DiaMedica Therapeutics $1.55 / -0.1 (-6.06%) 03/10/23 DiaMedica Therapeutics says does not hold deposits at Silicon Valley Bank 10/26/22 DiaMedica Therapeutics provides update on ReMEDy2 trial DMAC DiaMedica Therapeutics $1.55 / -0.1 (-6.06%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $1.55 / -0.1 (-6.06%) 03/28/23 DiaMedica Therapeutics reports FY22 EPS (52c), consensus (52c) 11/09/22 DiaMedica Therapeutics reports Q3 EPS (12c), consensus (15c) 05/17/23 DiaMedica Therapeutics Inc.
Earnings	DiaMedica Therapeutics reports FY22 EPS (52c), consensus (52c) » 16:31 03/28/23 03/28 16:31 03/28/23 16:31 DMAC DiaMedica Therapeutics $1.52 / -0.04 (-2.56%) "With the completion… "With the completion of the in-use study at hand, we look forward to continuing to work with the FDA to confirm that we have addressed all issues of the clinical hold and then prepare our complete response requesting a lifting of the clinical hold," commented Rick Pauls, DiaMedica's Chief Executive Officer. "We believe that we've addressed the issues raised by the FDA and are optimistic that the results of the in-use study will fully and finally confirm the cause of the hypotensive events." ShowHide Related Items >><< Company News Street Research Earnings Events DMAC DiaMedica Therapeutics $1.52 / -0.04 (-2.56%) 03/10/23 DiaMedica Therapeutics says does not hold deposits at Silicon Valley Bank 10/26/22 DiaMedica Therapeutics provides update on ReMEDy2 trial DMAC DiaMedica Therapeutics $1.52 / -0.04 (-2.56%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $1.52 / -0.04 (-2.56%) 11/09/22 DiaMedica Therapeutics reports Q3 EPS (12c), consensus (15c) 03/29/23 DiaMedica Therapeutics - DMAC
Hot Stocks	DiaMedica Therapeutics says does not hold deposits at Silicon Valley Bank » 16:53 03/10/23 03/10 16:53 03/10/23 16:53 DMAC DiaMedica Therapeutics $1.71 / -0.03 (-1.72%) In a regulatory 8-K… In a regulatory 8-K filing, the company states: "On March 10, 2023, DiaMedica Therapeutics Inc. announced that it does not hold cash deposits or securities at Silicon Valley Bank." ShowHide Related Items >><< Company News Street Research Earnings DMAC DiaMedica Therapeutics $1.71 / -0.03 (-1.72%) 10/26/22 DiaMedica Therapeutics provides update on ReMEDy2 trial DMAC DiaMedica Therapeutics $1.71 / -0.03 (-1.72%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $1.71 / -0.03 (-1.72%) 11/09/22 DiaMedica Therapeutics reports Q3 EPS (12c), consensus (15c)

Over a quarter ago
Earnings	DiaMedica Therapeutics reports Q3 EPS (12c), consensus (15c) » 16:36 11/09/22 11/09 16:36 11/09/22 16:36 DMAC DiaMedica Therapeutics $1.23 / +0.01 (+0.82%) DiaMedica reported total… DiaMedica reported total cash, cash equivalents and investments of $36.1 million, current liabilities of $1.5 million and working capital of $34.9 million as of September 30, 2022, compared to total cash, cash equivalents and investments of $45.1 million, $1.5 million in current liabilities and $43.9 million in working capital as of December 31, 2021. The decreases in cash and investments and in working capital were due primarily to cash used to fund operating activities during the nine months ended September 30, 2022. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DMAC DiaMedica Therapeutics $1.23 / +0.01 (+0.82%) 10/26/22 DiaMedica Therapeutics provides update on ReMEDy2 trial 07/06/22 DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold 07/06/22 DiaMedica Therapeutics trading resumes 07/06/22 DiaMedica Therapeutics to resume trading at 17:00ET DMAC DiaMedica Therapeutics $1.23 / +0.01 (+0.82%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $1.23 / +0.01 (+0.82%) 08/10/22 DiaMedica Therapeutics reports Q2 EPS (13c), consensus (18c) DMAC DiaMedica Therapeutics $1.23 / +0.01 (+0.82%) 07/07/22 Fly Intel: Pre-market Movers 07/06/22 Fly Intel: After-Hours Movers 11/08/22 31st Annual Healthcare Conference 11/17/22 13th Annual Alpha Select Conference
Hot Stocks	DiaMedica Therapeutics provides update on ReMEDy2 trial » 16:36 10/26/22 10/26 16:36 10/26/22 16:36 DMAC DiaMedica Therapeutics $1.42 / -0.04 (-2.74%) DiaMedica Therapeutics… DiaMedica Therapeutics announced that the Company has received further guidance from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on its ReMEDy2 Phase 2/3 trial for the treatment of acute ischemic stroke (AIS). The FDA stated it is maintaining its clinical hold at this time and that additional non-clinical data related to the materials used by a hospital in the IV infusion process is needed to resolve the clinical hold. In response to the FDA's clinical hold letter in July 2022 related to three serious adverse event cases of transient acute hypotension during intravenous infusion of DM199, the Company previously submitted to the FDA supporting in vitro data that the etiology (cause) is likely related to switching the type of intravenous (IV) bag used in the prior ReMEDy 1 trial, where no hypotensive episodes were reported, versus the current ReMEDy 2 trial. Hypotension is a known response to DM199 treatment. Significant differences in protein binding were observed between the two types of IV bags used in the studies that the Company believes altered the total amount of drug being administered. Following review of this data, the FDA requested an additional in-use in vitro stability study of the IV administration of DM199 which includes the IV tubing and mechanical infusion pump to further rule out any etiology other than IV bag protein binding. Preparations for these in vitro studies are already underway and the Company will request a Type A FDA meeting to confirm the study design and obtain additional guidance towards lifting the clinical hold and resuming the ReMEDy2 trial. The Company plans to provide an update on the timing of completion of the in-use in-vitro study and data submission following consultation with the FDA. Rick Pauls, DiaMedica's Chief Executive Officer, commented "Patient safety remains our top priority. We believe that we now have a clear path to resolving the clinical hold and we are highly focused on resuming the ReMEDy2 trial as quickly as possible." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DMAC DiaMedica Therapeutics $1.42 / -0.04 (-2.74%) 07/06/22 DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold 07/06/22 DiaMedica Therapeutics trading resumes 07/06/22 DiaMedica Therapeutics to resume trading at 17:00ET 07/06/22 DiaMedica says FDA puts clinical hold on Phase 2/3 ReMEDy2 trial DMAC DiaMedica Therapeutics $1.42 / -0.04 (-2.74%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer DMAC DiaMedica Therapeutics $1.42 / -0.04 (-2.74%) 08/10/22 DiaMedica Therapeutics reports Q2 EPS (13c), consensus (18c) DMAC DiaMedica Therapeutics $1.42 / -0.04 (-2.74%) 07/07/22 Fly Intel: Pre-market Movers 07/06/22 Fly Intel: After-Hours Movers 05/04/22 Meet DiaMedica Therapeutics: Fly exclusive interview with CEO Rick Pauls 11/17/22 13th Annual Alpha Select Conference
Earnings	DiaMedica Therapeutics reports Q2 EPS (13c), consensus (18c) » 17:22 08/10/22 08/10 17:22 08/10/22 17:22 DMAC DiaMedica Therapeutics $1.72 / +0.015 (+0.88%) DiaMedica reported total… DiaMedica reported total cash and investments of $38.4M, current liabilities of $1.5M and working capital of $37.6M as of June 30, 2022, compared to total cash and investments of $45.1M, $1.5M in current liabilities and $43.9M in working capital as of December 31, 2021. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DMAC DiaMedica Therapeutics $1.72 / +0.015 (+0.88%) 07/06/22 DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold 07/06/22 DiaMedica Therapeutics trading resumes 07/06/22 DiaMedica Therapeutics to resume trading at 17:00ET 07/06/22 DiaMedica says FDA puts clinical hold on Phase 2/3 ReMEDy2 trial DMAC DiaMedica Therapeutics $1.72 / +0.015 (+0.88%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer 09/27/21 Roth MKM DiaMedica price target lowered to $24 from $32 at Roth Capital DMAC DiaMedica Therapeutics $1.72 / +0.015 (+0.88%) 03/14/22 DiaMedica Therapeutics reports Q4 EPS (65c), consensus (18c) DMAC DiaMedica Therapeutics $1.72 / +0.015 (+0.88%) 07/07/22 Fly Intel: Pre-market Movers 07/06/22 Fly Intel: After-Hours Movers 05/04/22 Meet DiaMedica Therapeutics: Fly exclusive interview with CEO Rick Pauls 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 08/11/22 DiaMedica Therapeutics - DMAC
On The Fly	Fly Intel: Pre-market Movers » 08:55 07/07/22 07/07 08:55 07/07/22 08:55 SGEN Seagen $175.15 / -1.78 (-1.01%) , EDR Endeavor Group $21.16 / -0.39 (-1.81%) , LAMR Lamar Advertising $88.37 / +0.105 (+0.12%) , GME GameStop $117.34 / -2.82 (-2.35%) , SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) , ENSV Enservco $1.76 / -0.11 (-5.88%) , HELE Helen of Troy $169.87 / +1.66 (+0.99%) , MRK Merck $93.16 / +0.52 (+0.56%) , CNSL Consolidated Communications $6.98 / -0.235 (-3.26%) , DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) , BA Boeing $136.29 / -1.55 (-1.12%) , CTMX CytomX Therapeutics $1.96 / +0.015 (+0.77%) Check out this morning's… Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SPCE SGEN MRK HELE GME ENSV EDR DMAC CTMX CNSL BA SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) 07/06/22 Virgin Galactic selects Boeing's Aurora to build new motherships 05/05/22 Virgin Galactic expects to launch commercial service in Q1 of 2023 05/05/22 Virgin Galactic sees Q2 free cash flow of ($80M)-($90M) 02/22/22 Virgin Galactic sees Q1 free cash flow of ($85M) to ($75M) SGEN Seagen $175.15 / -1.78 (-1.01%) 07/03/22 Seagen announces results from pivotal MOUNTAINEER trial 07/02/22 Seagen says Tukysa combo shows clinically meaningful antitumor activity in trial 06/17/22 Seattle Genetics trading resumes 06/17/22 Seagen jumps 10% to $161.79 after WSJ report of Merck interest MRK Merck $93.16 / +0.52 (+0.56%) 06/28/22 G1 Therapeutics announces addition of Lee to board of directors 06/27/22 AstraZeneca, Merck announce LYNPARZA receives positive opinion from CHMP 06/27/22 AstraZeneca's Lynparza recommended for E.U. approval by CHMP in breast cancer HELE Helen of Troy $169.87 / +1.66 (+0.99%) 05/10/22 Hydro Flask receives U.S. ITC General Exclusion Order to combat counterfeiting 04/27/22 Helen of Troy: Noel Geoffroy to join company as COO on May 9 GME GameStop $117.34 / -2.82 (-2.35%) 07/06/22 GameStop announces four-for-one stock split 06/14/22 May 2022 video game spending fell 19% year-over-year, says NPD 06/01/22 GameStop up 2% after Q1 sales beat expectations 05/27/22 GameStop rises 10.5% ENSV Enservco $1.76 / -0.11 (-5.88%) 04/25/22 Enservco appoints Patterson as CFO 04/18/22 Enservco delays filing of Form 10-K to restate 2021 Form 10-Qs 04/05/22 Enservco president, CFO Marjorie Hargrave to depart April 22 03/28/22 Enservco to amend financial statements for first three quarters of 2021 EDR Endeavor Group $21.16 / -0.39 (-1.81%) 06/30/22 Light & Wonder enters into amended purchase pact for sale of OpenBet to Endeavor 05/13/22 Endeavor Group rises 22.0% 05/13/22 Endeavor Group rises 21.3% 02/14/22 Third Point buys Rivian, exits Meta in Q4 DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 07/06/22 DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold 07/06/22 DiaMedica Therapeutics trading resumes 07/06/22 DiaMedica Therapeutics to resume trading at 17:00ET 07/06/22 DiaMedica says FDA puts clinical hold on Phase 2/3 ReMEDy2 trial CTMX CytomX Therapeutics $1.96 / +0.015 (+0.77%) 07/06/22 CytomX Therapeutics trading resumes 07/06/22 CytomX Therapeutics to resume trading at 4:35 pm ET 07/06/22 CytomX reports Arm A of praluzatamab ravtansine trial met primary endpoint 07/06/22 CytomX Therapeutics trading halted, news pending CNSL Consolidated Communications $6.98 / -0.235 (-3.26%) 05/05/22 Consolidated Communications sees FY22 adjusted EBITDA $410M-$425M 03/08/22 Searchlight evaluating potential acquisition of Consolidated Communications 03/03/22 Consolidated Communications to sell Kansas City assets to Alinda Capital 03/03/22 Consolidated Communications to sell Kansas City assets to Alinda Capital BA Boeing $136.29 / -1.55 (-1.12%) 07/01/22 Airbus announces 292 orders for A320 planes from Chinese airlines 06/23/22 Boeing signs on for Aireon ADS-B data services 06/21/22 Boeing elects David Gitlin to Board of Directors SGEN EDR LAMR GME SPCE ENSV HELE MRK CNSL DMAC BA CTMX SGEN Seagen $175.15 / -1.78 (-1.01%) 06/29/22 Raymond James Seagen initiated with an Outperform at Raymond James 06/28/22 Piper Sandler Sutro Biopharma price target raised to $16 from $14 at Piper Sandler 06/27/22 TD Cowen Merck price target raised to $102 from $95 at Cowen 06/24/22 Mizuho Merck deal would add 'novel and validated technology,' says Mizuho EDR Endeavor Group $21.16 / -0.39 (-1.81%) 07/07/22 Citi Endeavor Group upgraded to Buy from Neutral at Citi 07/01/22 Barclays Endeavor Group price target raised to $28 from $27 at Barclays 06/23/22 Credit Suisse Endeavor Group assumed with an Outperform at Credit Suisse 06/15/22 Morgan Stanley Morgan Stanley upgrades Liberty Formula One, names Endeavor top pick LAMR Lamar Advertising $88.37 / +0.105 (+0.12%) 07/07/22 Citi Lamar Advertising upgraded to Buy from Neutral at Citi 06/10/22 Morgan Stanley Lamar downgraded to Equal Weight on recession risk at Morgan Stanley 06/10/22 Morgan Stanley Lamar Advertising downgraded to Equal Weight from Overweight at Morgan Stanley 03/29/22 Wolfe Research Lamar Advertising initiated with a Peer Perform at Wolfe Research GME GameStop $117.34 / -2.82 (-2.35%) 05/26/22 Wedbush Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns 03/28/22 B. Riley Bed Bath & Beyond price target raised to $26 from $19 at B. Riley 03/18/22 Wedbush GameStop price target lowered to $30 from $45 at Wedbush 03/08/22 BofA Bed Bath's buybuy BABY 'not worth' several billion dollars, says BofA SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) 06/21/22 Wells Fargo Virgin Galactic initiated with an Underweight at Wells Fargo 05/09/22 Truist Virgin Galactic downgraded to Hold from Buy at Truist 05/09/22 Truist Virgin Galactic downgraded to Hold from Buy at Truist 05/06/22 Canaccord Virgin Galactic downgraded to Hold at Canaccord after commercial launch delay ENSV Enservco $1.76 / -0.11 (-5.88%) HELE Helen of Troy $169.87 / +1.66 (+0.99%) 06/28/22 CL King Helen of Troy price target lowered to $206 from $282 at CL King 04/22/22 Oppenheimer Oppenheimer expects strong Q4, inline guidance for Helen of Troy 02/07/22 Sidoti Helen of Troy upgraded to Buy from Neutral at Sidoti 12/01/21 DA Davidson Helen of Troy price target raised to $266 from $254 at DA Davidson MRK Merck $93.16 / +0.52 (+0.56%) 07/07/22 Daiwa Merck upgraded to Outperform from Neutral at Daiwa (yesterday) 07/06/22 Daiwa Merck upgraded to Buy from Neutral at Daiwa CNSL Consolidated Communications $6.98 / -0.235 (-3.26%) 07/07/22 Citi Consolidated Communications downgraded to Sell from Neutral at Citi 03/08/22 Citi Consolidated Communications upgraded to Neutral from Sell at Citi 03/04/22 Wells Fargo Consolidated Communications downgraded to Equal Weight from Overweight at Wells Fargo 03/04/22 Citi Consolidated Communications downgraded to Sell from Neutral at Citi DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 07/07/22 Lake Street DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer 09/27/21 Roth MKM DiaMedica price target lowered to $24 from $32 at Roth Capital BA Boeing $136.29 / -1.55 (-1.12%) 07/01/22 Citi Boeing optimistic regarding FAA clearance of 787, says Citi 06/16/22 Citi Boeing upgraded to Buy from Neutral at Citi 06/15/22 Susquehanna Boeing delivery estimates lowered for Q2 at Susquehanna 06/14/22 Morgan Stanley Boeing's May deliveries report 'lackluster,' says Morgan Stanley CTMX CytomX Therapeutics $1.96 / +0.015 (+0.77%) 07/07/22 Jefferies CytomX Therapeutics downgraded to Hold from Buy at Jefferies 07/07/22 Wedbush Wedbush downgrades CytomX Therapeutics to Neutral, lowers price target to $2 07/07/22 BMO Capital CytomX Therapeutics price target lowered to $3 from $9 at BMO Capital 07/07/22 BTIG CytomX Therapeutics price target lowered to $8 from $16 at BTIG SPCE SGEN MRK LAMR HELE GME ENSV EDR DMAC CTMX CNSL BA SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) 05/05/22 Virgin Galactic reports Q1 EPS (36c), consensus (32c) 05/05/22 Notable companies reporting after market close 02/22/22 Virgin Galactic reports Q4 EPS (31c), consensus (34c) 02/22/22 Notable companies reporting after market close SGEN Seagen $175.15 / -1.78 (-1.01%) 04/28/22 Seagen sees FY22 total revenue $1.665B-$1.745B, consensus $1.78B 04/28/22 Seagen reports Q1 EPS (74c), consensus ($1.00) 02/10/22 Seagen sees FY22 total revenue $1.67B-$1.75B, consensus $2.16B 02/09/22 Seagen reports Q4 EPS (95c), consensus (83c) MRK Merck $93.16 / +0.52 (+0.56%) 04/28/22 Merck raises FY22 adjusted EPS view to $7.24-$7.36, consensus $7.24 04/28/22 Merck reports Q1 adjusted EPS $2.14, consensus $1.83 04/27/22 Notable companies reporting before tomorrow's open LAMR Lamar Advertising $88.37 / +0.105 (+0.12%) 05/05/22 Lamar Advertising raises FY22 AFFO view to $7.20-$7.35 from $7.03-$7.18 05/05/22 Lamar Advertising reports Q1 EPS 91c, consensus 72c 02/25/22 Lamar Advertising sees FY22 AFFO $7.03-$7.18 02/25/22 Lamar Advertising reports Q4 EPS $1.21, consensus $1.18 HELE Helen of Troy $169.87 / +1.66 (+0.99%) 07/07/22 Helen of Troy sees 2023 consolidated adjusted EPS $9.85-$10.35, consensus $13.17 07/07/22 Helen of Troy reports Q1 core adjusted EPS $2.41, consensus $2.54 04/27/22 Helen of Troy sees FY23 adjusted EPS $12.73-$13.03, consensus $12.76 04/27/22 Helen of Troy reports Q4 adjusted EPS $2.51, consensus $2.01 GME GameStop $117.34 / -2.82 (-2.35%) 06/01/22 GameStop reports Q1 EPS ($2.08), consensus ($1.45) 06/01/22 Notable companies reporting after market close 03/17/22 GameStop reports Q4 EPS ($1.94) vs $1.19 last year 03/17/22 Notable companies reporting after market close ENSV Enservco $1.76 / -0.11 (-5.88%) 07/07/22 Enservco sees Q1 revenue up 58%-64% over 1Q21 07/07/22 Enservco reports Q4 EPS (27c) vs. (69c) last year EDR Endeavor Group $21.16 / -0.39 (-1.81%) 05/12/22 Endeavor Group raises FY22 revenue view to $5.235B-$5.475B from $5.2B-$5.45B 05/12/22 Endeavor Group reports Q1 EPS $1.16, consensus 42c 03/16/22 Endeavor sees FY22 revenue $5.2B-$5.45B, consensus $5.11B 03/16/22 Endeavor reports Q4 EPS (7c), consensus 17c DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 03/14/22 DiaMedica Therapeutics reports Q4 EPS (65c), consensus (18c) CTMX CytomX Therapeutics $1.96 / +0.015 (+0.77%) 03/01/22 CytomX Therapeutics reports Q4 revenue $19.7M, consensus $24.51M CNSL Consolidated Communications $6.98 / -0.235 (-3.26%) 05/05/22 Consolidated Communications reports Q1 adjusted EPS 2c, consensus (3c) 03/03/22 Consolidated Communications reports Q4 adjusted EPS 13c, consensus 4c BA Boeing $136.29 / -1.55 (-1.12%) 04/27/22 Boeing reports Q1 core EPS ($2.75), consensus (12c) 04/26/22 Notable companies reporting before tomorrow's open 04/11/22 Ultra Clean cuts Q1 revenue view to $560M-$570M from $580M-$630M SGEN GME EDR BA SGEN Seagen $175.15 / -1.78 (-1.01%) 07/07/22 Merck in advanced talks to buy Seagen for $40B+, WSJ reports 06/24/22 Merck moving forward with potential Seagen deal, WSJ reports 06/17/22 Merck, other suitors interested in acquiring Seagen, WSJ reports 06/17/22 Merck considering acquisition of Seagen, WSJ reports GME GameStop $117.34 / -2.82 (-2.35%) 05/19/22 Former GameStop employee sues company over NY manual labor law, Polygon says 03/26/22 GameStop crypto dream 'a long shot,' Barron's says 03/06/22 Chewy co-founder Ryan Cohen takes large stake in Bed Bath & Beyond, WSJ says 01/07/22 Games analyst 'very skeptical' of GameStop's new plans EDR Endeavor Group $21.16 / -0.39 (-1.81%) 04/07/22 Formula 1, WWE could be acquisition targets for streaming companies, CNBC says BA Boeing $136.29 / -1.55 (-1.12%) 06/20/22 Air India holding talks to buy 300 narrowbody jets, Bloomberg reports 06/17/22 Boeing 'almost there' on 787 Dreamliner return, Bloomberg reports 06/16/22 China Southern Airlines conducts test flights with 737 MAX, Reuters reports 06/14/22 EU, U.S. regulators to meet with Boeing next week over 777X, Reuters says SPCE SGEN LAMR HELE GME EDR DMAC CNSL BA SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) 06/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/22 What You Missed On Wall Street On Monday 05/09/22 What You Missed On Wall Street This Morning SGEN Seagen $175.15 / -1.78 (-1.01%) 06/24/22 What You Missed On Wall Street On Friday 06/24/22 What You Missed On Wall Street This Morning 06/24/22 Fly Intel: Pre-market Movers 06/17/22 What You Missed On Wall Street On Friday LAMR Lamar Advertising $88.37 / +0.105 (+0.12%) 06/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/29/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations HELE Helen of Troy $169.87 / +1.66 (+0.99%) 02/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations GME GameStop $117.34 / -2.82 (-2.35%) 07/06/22 Fly Intel: After-Hours Movers 07/06/22 What You Missed This Week in Video Games 06/28/22 What You Missed This Week in Video Games 06/14/22 What You Missed This Week in Video Games EDR Endeavor Group $21.16 / -0.39 (-1.81%) 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/12/22 Fly Intel: After-Hours Movers DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 05/04/22 Meet DiaMedica Therapeutics: Fly exclusive interview with CEO Rick Pauls CNSL Consolidated Communications $6.98 / -0.235 (-3.26%) 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BA Boeing $136.29 / -1.55 (-1.12%) 06/16/22 What You Missed On Wall Street On Thursday 06/16/22 What You Missed On Wall Street This Morning 06/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/14/22 What You Missed On Wall Street On Tuesday 08/08/22 Biotechnology Conference 07/07/22 Helen of Troy - HELE 07/27/22 Boeing - BA 07/28/22 Merck - MRK 08/03/22 Lamar Advertising - LAMR 08/04/22 Virgin Galactic - SPCE 01/29/23 PDUFA Date for new sBLA for KEYTRUDA 08/09/22 Helen of Troy 08/24/22 Helen of Troy Ltd. 10/04/22 Merck SPCE MRK GME ENSV BA SPCE Virgin Galactic $6.44 / -0.045 (-0.69%) 06/22/22 Virgin Galactic call volume above normal and directionally bullish 05/10/22 Virgin Galactic call volume above normal and directionally bullish 05/05/22 Virgin Galactic call volume above normal and directionally bullish 05/05/22 Unusually active option classes on open May 5th MRK Merck $93.16 / +0.52 (+0.56%) 07/06/22 Unusually active option classes on open July 6th 06/01/22 Merck put volume heavy and directionally bearish 05/31/22 Merck put volume heavy and directionally bearish 05/18/22 Merck put volume heavy and directionally bearish GME GameStop $117.34 / -2.82 (-2.35%) 06/13/22 GameStop put volume heavy and directionally bearish 06/08/22 GameStop call volume above normal and directionally bullish 06/01/22 GameStop options imply 13.7% move in share price post-earnings 05/27/22 Unusually active option classes on open May 27th ENSV Enservco $1.76 / -0.11 (-5.88%) 03/30/22 Four new option listings and one option delisting on March 30th BA Boeing $136.29 / -1.55 (-1.12%) 06/28/22 Unusually active option classes on open June 28th 06/16/22 Early notable gainers among liquid option names on June 16th 06/15/22 Early notable gainers among liquid option names on June 15th 03/21/22 Unusually active option classes on open March 21st
Recommendations	DiaMedica Therapeutics price target lowered to $8 from $14 at Lake Street » 08:44 07/07/22 07/07 08:44 07/07/22 08:44 DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) Lake Street analyst… Lake Street analyst Thomas Flaten lowered the firm's price target on DiaMedica Therapeutics to $8 from $14 and keeps a Buy rating on the shares after the company announced the FDA has placed a clinical hold on the ReMEDy2 stroke study. While "not positive," he believes the issue leading to the hold may be resolved in short order and that the company should then be able to restart enrollment, said Flaten, who expresses confidence that there will not be a significant delay to the interim analysis readout. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 07/06/22 DiaMedica Therapeutics down 38% to $1.25 after placing DM199 on clinical hold 07/06/22 DiaMedica Therapeutics trading resumes 07/06/22 DiaMedica Therapeutics to resume trading at 17:00ET 07/06/22 DiaMedica says FDA puts clinical hold on Phase 2/3 ReMEDy2 trial DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 07/07/22 Craig-Hallum DiaMedica Therapeutics price target lowered to $12 from $18 at Craig-Hallum 07/07/22 Oppenheimer DiaMedica Therapeutics downgraded to Perform from Outperform at Oppenheimer 09/27/21 Roth MKM DiaMedica price target lowered to $24 from $32 at Roth Capital DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 03/14/22 DiaMedica Therapeutics reports Q4 EPS (65c), consensus (18c) DMAC DiaMedica Therapeutics $2.03 / + (+0.00%) 07/06/22 Fly Intel: After-Hours Movers 05/04/22 Meet DiaMedica Therapeutics: Fly exclusive interview with CEO Rick Pauls 08/08/22 Biotechnology Conference

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial